Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.62%
#4 aPriori aPriori +181.23%
#5 Bedrock Bedrock +79.53%
#6 Cysic Cysic +51.82%
#7 Prom Prom +46.77%
#8 Playnance Playnance +34.89%
#9 Bitway Bitway +29.28%
#10 COTI COTI +25.62%
Coin of the day
Wrapped One Wrapped One
設定
言語
日本
通貨
USD
テーマ
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
株式のランク #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
株価
$0.0001
最終同期: 2026-07-02
時価総額
$2.20K
変化（1日）
0.00%
変化（1年）
0.00%
国
CA
取引 Cotinga Pharmaceuticals Inc. (COTQF)

カテゴリー

Healthcare
Cotinga Pharmaceuticals Inc.（COTQF）の収益
Aug 2026 時点の収益 TTM: 0
Cotinga Pharmaceuticals Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cotinga Pharmaceuticals Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR